Welcome to our dedicated page for Fuse Group news (Ticker: FUST), a resource for investors and traders seeking the latest updates and insights on Fuse Group stock.
Fuse Group Holding Inc. (FUST) reports company developments tied to its business-development activities as an OTCQB issuer that has described itself as pursuing opportunities in mining and biotech. News releases have covered consulting and marketing-services arrangements, including work intended to support North American market expansion for a digital marketing and IT consulting client. Prior announcements also referenced strategic interest in biotech research and development, while the company's public updates remain centered on diversification and business-development activity.
Summary not available.
Fuse Group Holding Inc. (OTCQB: FUST) announced a letter of intent to acquire E-Mo Biotech Holding Inc. for $100 million, payable in common stock at $1.00 per share. The acquisition will allow Fuse to enter the biotech sector, focusing on vaccine and treatment development, particularly against SARS-CoV-2. E-Mo is currently applying for FDA approval for a phase 4 clinical trial using an existing polio vaccine for COVID-19. This strategic move aims to aid in pandemic control while expanding Fuse's operational landscape within biotechnology.